These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 18338371)
1. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state. Sadler K; Zhang Y; Xu J; Yu Q; Tam JP Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371 [TBL] [Abstract][Full Text] [Related]
2. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment. Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433 [TBL] [Abstract][Full Text] [Related]
4. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex. Welman M; Lemay G; Cohen EA Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629 [TBL] [Abstract][Full Text] [Related]
5. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein. Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170 [TBL] [Abstract][Full Text] [Related]
6. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Luftig MA; Mattu M; Di Giovine P; Geleziunas R; Hrin R; Barbato G; Bianchi E; Miller MD; Pessi A; Carfí A Nat Struct Mol Biol; 2006 Aug; 13(8):740-7. PubMed ID: 16862157 [TBL] [Abstract][Full Text] [Related]
7. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice. Qi Z; Pan C; Lu H; Shui Y; Li L; Li X; Xu X; Liu S; Jiang S Biochem Biophys Res Commun; 2010 Jul; 398(3):506-12. PubMed ID: 20599765 [TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41. Viveros M; Dickey C; Cotropia JP; Gevorkian G; Larralde C; Broliden K; Levi M; Burgess A; Cao C; Weiner DB; Agadjanyan MG; Ugen KE Virology; 2000 Apr; 270(1):135-45. PubMed ID: 10772986 [TBL] [Abstract][Full Text] [Related]
9. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41. Rey-Cuillé MA; Svab J; Benferhat R; Krust B; Briand JP; Muller S; Hovanessian AG J Pharm Pharmacol; 2006 Jun; 58(6):759-67. PubMed ID: 16734977 [TBL] [Abstract][Full Text] [Related]
10. Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes. Zipeto D; Matucci A; Ripamonti C; Scarlatti G; Rossolillo P; Turci M; Sartoris S; Tridente G; Bertazzoni U Microbes Infect; 2006 May; 8(6):1424-33. PubMed ID: 16702010 [TBL] [Abstract][Full Text] [Related]
11. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Cardoso RM; Zwick MB; Stanfield RL; Kunert R; Binley JM; Katinger H; Burton DR; Wilson IA Immunity; 2005 Feb; 22(2):163-73. PubMed ID: 15723805 [TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6. Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506 [TBL] [Abstract][Full Text] [Related]
13. Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. Opalka D; Pessi A; Bianchi E; Ciliberto G; Schleif W; McElhaugh M; Danzeisen R; Geleziunas R; Miller M; Eckert DM; Bramhill D; Joyce J; Cook J; Magilton W; Shiver J; Emini E; Esser MT J Immunol Methods; 2004 Apr; 287(1-2):49-65. PubMed ID: 15099755 [TBL] [Abstract][Full Text] [Related]
14. Human monoclonal antibody 98-6 reacts with the fusogenic form of gp41. Taniguchi Y; Zolla-Pazner S; Xu Y; Zhang X; Takeda S; Hattori T Virology; 2000 Aug; 273(2):333-40. PubMed ID: 10915604 [TBL] [Abstract][Full Text] [Related]
15. Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1. Cleveland SM; Jones TD; Dimmock NJ J Gen Virol; 2000 May; 81(Pt 5):1251-60. PubMed ID: 10769067 [TBL] [Abstract][Full Text] [Related]
16. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. Zhang H; Huang Y; Fayad R; Spear GT; Qiao L J Virol; 2004 Aug; 78(15):8342-8. PubMed ID: 15254206 [TBL] [Abstract][Full Text] [Related]
17. [Construction of peptide mimetics of an epitope of the human immunodeficiency virus (HIV-1) gp41 protein, recognized by virus-neutralizing antibodies 2F5]. Tumanova OIu; Kuvshinov VN; Azaev MSh; Masharskiĭ AE; Klimov NA; Kozlov AP; Il'ichev AA; Sandakhchiev LS Mol Biol (Mosk); 2001; 35(1):146-51. PubMed ID: 11234374 [TBL] [Abstract][Full Text] [Related]
18. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope. Li J; Chen X; Jiang S; Chen YH Biochem Biophys Res Commun; 2008 Nov; 376(1):60-4. PubMed ID: 18762167 [TBL] [Abstract][Full Text] [Related]
19. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 (CBD1) contains several overlapping neutralizing epitopes. Benferhat R; Krust B; Rey-Cuillé MA; Hovanessian AG Vaccine; 2009 Jun; 27(27):3620-30. PubMed ID: 19464543 [TBL] [Abstract][Full Text] [Related]
20. Antiviral properties of two trimeric recombinant gp41 proteins. Delcroix-Genête D; Quan PL; Roger MG; Hazan U; Nisole S; Rousseau C Retrovirology; 2006 Mar; 3():16. PubMed ID: 16515685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]